Outcomes, challenges and prospects of emicizumab prophylaxis in Sub-Saharan Africa – Insights from the Tanzanian experience
Rebbecca Wughanga Mwakichako
Muhimbili University of Health and Allied SciencesDar es Salaam, Tanzania
Profil OrcidRecherchez cet auteur sur
, Rajabu Hussein Mnkugwe
Muhimbili University of Health and Allied SciencesDar es Salaam, Tanzania
Profil OrcidRecherchez cet auteur sur
, Clara Chamba
Muhimbili University of Health and Allied SciencesDar es Salaam, Tanzania
Profil OrcidRecherchez cet auteur sur
, Peter Kunambi
Muhimbili University of Health and Allied SciencesDar es Salaam, Tanzania
Profil OrcidRecherchez cet auteur sur
, , , Michelle Munroe
Muhimbili University of Health and Allied SciencesDar es Salaam, Tanzania
Profil OrcidRecherchez cet auteur sur
, Gladys Kaaya
Muhimbili University of Health and Allied SciencesDar es Salaam, Tanzania
Profil OrcidRecherchez cet auteur sur
, Mwashungi Ally
Muhimbili University of Health and Allied SciencesDar es Salaam, Tanzania
Profil OrcidRecherchez cet auteur sur
, Ahlam Nasser
Muhimbili University of Health and Allied SciencesDar es Salaam, Tanzania
Profil OrcidRecherchez cet auteur sur
, William Mawala
Muhimbili University of Health and Allied SciencesDar es Salaam, Tanzania
Profil OrcidRecherchez cet auteur sur
, Magdalena Lyimo
Muhimbili University of Health and Allied SciencesDar es Salaam, Tanzania
Profil OrcidRecherchez cet auteur sur
, Johnny Mahlangu
University of the Witwatersrand JohannesburgJohannesburg, South Africa
Profil OrcidRecherchez cet auteur sur
et Stella Rwezaula
Muhimbili University of Health and Allied SciencesDar es Salaam, Tanzania
Profil OrcidRecherchez cet auteur sur
19 mars 2025
À propos de cet article
Catégorie d'article: Clinical Research
Publié en ligne: 19 mars 2025
Pages: 15 - 22
DOI: https://doi.org/10.2478/jhp-2025-0005
Mots clés
© 2025 Rebbecca Wughanga Mwakichako et al., published by Sciendo
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Figure 1.
Figure 2:
Sociodemographic and clinical characteristics of study participants
| Below 5 years | 14 | 25.5% |
| 5–18 years | 34 | 61.8% |
| Above 18 years | 7 | 12.7% |
| 8 (4,14) | ||
| Dar es Salaam | 28 | 50.9% |
| Outside Dar es Salaam | 27 | 49.1% |
| Severe (<1%) | 28 | 50.9% |
| Moderate (1–5%) | 22 | 40.0% |
| Mild (6–40%) | 4 | 7.3% |
| Unknown | 1 | 1.8% |
| Present | 19 | 34.6% |
| Absent | 36 | 65.4% |
| 8(5,16) | ||
| Present | 19 | 34.6% |
| Absent | 36 | 65.4% |
Association between sociodemographic and clinical characteristics and spontaneous bleeding
| < 5 | 1 (7.1%) | 13 (92.9%) | < 0.0001 | Ref | ||
| 5–18 | 5 (15.2%) | 28 (84.8%) | 2.12 | 0.27–16.54 | 0.473 | |
| >18 | 5 (83.3%) | 1 (16.7%) | 11.67 | 1.71–79.76 | 0.012 | |
| Mild | 1 (25.0%) | 3 (75.0%) | 0.885 | Ref | ||
| Moderate | 4 (18.2%) | 18 (81.8%) | 0.73 | 0.11–4.94 | 0.744 | |
| Severe | 6 (23.1%) | 20 (76.9%) | 0.92 | 0.15–5.79 | 0.932 | |
| Adherence | 6 (14.6%) | 35 (85.4%) | 0.098 | 0.35 | 0.13–0.95 | 0.040 |
| Non-adherence | 5 (41.7%) | 7 (58.3%) | Ref | |||
| Dar-es-Salaam | 5 (19.2%) | 21 (80.8%) | 1.000 | Ref | ||
| Outside Dar-es-Salaam | 6 (22.2%) | 21 (77.8%) | 1.16 | 0.40–3.33 | 0.789 | |
| Exemption | 0 (0.0%) | 1 (100.0%) | 1.000 | 0.80 | 0.68–0.95 | 0.010 |
| Insured | 7 (23.3%) | 23 (76.7%) | 0.99 | 0.80–1.22 | 0.900 | |
| Private | 2 (25.0%) | 6 (75.0%) | 1.00 | 0.75–1.34 | 1.000 | |
| Public (cost sharing) | 4 (25.0%) | 12 (75.0%) | Ref | |||